Definium Therapeutics, Inc.
DFTXNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $3.79B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $10.47$49.70
- Volume (live)
- -
- Avg. volume (3M)
- 2.32M
Definium Therapeutics (DFTX) Stock Price & Financial Analysis
Definium Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $32.02 - $34.15 |
|---|---|
| 52-Week High | $49.70 |
| 52-Week Low | $10.47 |
| Open | $34.07 |
| Volume (last close) | 1.93M |
| Average Volume (3M) | 2.32M |
| 50-Day MA | $39.93 |
|---|---|
| 200-Day MA | $28.30 |
| 1-Year Change | +150.99% |
| Market Cap | 3.79B |
|---|---|
| Shares Outstanding | 110.68M |
| Price to Book (P/B) | 4.13 |
| EV/EBITDA | -9.34 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Definium Therapeutics at a Glance
As of the Oct 16, 2026 close, Definium Therapeutics (DFTX) has a market capitalization of $3.79B.
As of its latest reported balance sheet, it holds $655.27M in cash and securities against $36.47M of debt, a net cash position of $618.80M.
Definium Therapeutics does not currently pay a dividend.
The share price is up 151.0% over the past year. At $32.10 (the Oct 16, 2026 close) it sits within its 52-week range of $10.46 to $49.70, above its 200-day moving average of $28.30.
Based on 15 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $74.36, 131.7% above the Oct 16, 2026 close.
Frequently Asked Questions About Definium Therapeutics
What is the current stock price for DFTX?
As of the Oct 16, 2026 close, DFTX stock trades at $32.10. The 52-week range is $10.47–$49.70, with a day range of $32.02–$34.15.
What is the P/E ratio for DFTX?
The P/E ratio (Price-to-Earnings) for DFTX is shown in the Key Statistics section. This valuation metric helps compare Definium Therapeutics, Inc. to industry peers.
Does DFTX pay dividends?
Definium Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DFTX?
Based on ratings from 15 professional analysts over the last 90 days, the consensus for DFTX is Buy. The average 12-month price target is $74.36, a 131.7% upside from the Oct 16, 2026 close of $32.10.
What is the market cap of DFTX?
As of the Oct 16, 2026 close, Definium Therapeutics's market capitalization is $3.55B, classifying it as a mid-cap company. Definium Therapeutics operates in the Healthcare sector within the Biotechnology industry.